CLPT (ClearPoint Neuro) Debt-to-Asset : 0.74 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLPT ClearPoint Neuro Inc CLPT
73 GF Score
Price $13.96
GF Value $14.54
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is ClearPoint Neuro Debt-to-Asset?

ClearPoint Neuro CLPT -0.71% 73 Debt-to-Asset is 0.74 as of Jun. 2026. GuruFocus rates CLPT with a GF Score™ of 73/100 and a GF Value™ of $14.54 (Fairly Valued). The stock has 8 warning signs investors should review.

ClearPoint Neuro's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.19 Mil. ClearPoint Neuro's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $63.75 Mil. ClearPoint Neuro's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2026 was $86.74 Mil. ClearPoint Neuro's debt to asset for the quarter that ended in Jun. 2026 was 0.74.

ClearPoint Neuro  (NAS:CLPT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ClearPoint Neuro Debt-to-Asset Related Terms

ClearPoint Neuro Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for ClearPoint Neuro's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ClearPoint Neuro Debt-to-Asset Chart

ClearPoint Neuro Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.22 0.33 0.09 0.60

ClearPoint Neuro Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.56 0.59 0.60 0.68 0.74

CLPT vs SGHT, SENS, NPCE: Debt-to-Asset Comparison

For the Medical Devices subindustry, ClearPoint Neuro's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ClearPoint Neuro Debt-to-Asset vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ClearPoint Neuro's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ClearPoint Neuro's Debt-to-Asset falls into.


CLPT
73GF Score
ClearPoint Neuro Inc CLPT
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ClearPoint Neuro Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ClearPoint Neuro's Debt-to-Asset for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.694 + 57.538) / 97.747
=0.60

ClearPoint Neuro's Debt-to-Asset for the quarter that ended in Jun. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.194 + 63.752) / 86.741
=0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.74 mean?
ClearPoint Neuro (CLPT) has a Debt-to-Asset of 0.74 as of Jun. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on ClearPoint Neuro and its competitors.
Is ClearPoint Neuro's Debt-to-Asset too high?
ClearPoint Neuro's current Debt-to-Asset is 0.74. Overall, ClearPoint Neuro has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ClearPoint Neuro's Debt-to-Asset compare to SGHT and SENS?
ClearPoint Neuro's Debt-to-Asset of 0.74 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Medical Devices & Instruments company?
A good Debt-to-Asset depends on the Medical Devices & Instruments industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on ClearPoint Neuro and its competitors. ClearPoint Neuro's current Debt-to-Asset is 0.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ClearPoint Neuro stock overvalued right now?
Based on GuruFocus' analysis, ClearPoint Neuro (CLPT) is currently considered Fairly Valued. The stock's GF Value™ is $14.54, compared to a current price of $13.96 — trading 4% below its estimated fair value. The current Debt-to-Asset is 0.74. ClearPoint Neuro's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For ClearPoint Neuro (CLPT), the current Debt-to-Asset is 0.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ClearPoint Neuro (CLPT) Overvalued in 2026?

Based on GuruFocus' analysis, ClearPoint Neuro stock appears to be undervalued. The current stock price of $13.96 is trading 4% below its estimated GF Value™ of $14.54. GuruFocus considers ClearPoint Neuro to be Fairly Valued.

Key valuation signals for CLPT:

  • Debt-to-Asset: 0.74
  • GF Value™: $14.54 vs. price of $13.96 (4% below fair value)
  • GF Score™: 73/100 with 8 warning signs

No single metric tells the full story. See the CLPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ClearPoint Neuro Business Description

Address 120 S. Sierra Avenue, Suite 100, Solana Beach, CA, USA, 92075
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
73GF Score

Get the complete analysis for CLPT

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.96
Price
$14.54
GF Value